预防性左乙拉西坦用于预防脑出血急性期癫痫发作的安全性和有效性(PEACH):一项随机、双盲、安慰剂对照的3期试验
PEACH试验在法国3个卒中单元纳入50例发病24小时内的非创伤性脑出血患者,随机接受左乙拉西坦(静脉500 mg每12小时)或安慰剂治疗6周。纳入后72小时内,左乙拉西坦组19例中3例(16%)出现临床或脑电图癫痫发作,安慰剂组23例中10例(43%)出现(比值比0.16,95%CI 0.03-0.94,p=0.043),均为脑电图发作。作者认为左乙拉西坦可能有效预防脑出血急性期癫痫发作,需更大规模研究确定其能否改善功能预后。
要点
- 脑出血后72小时内,左乙拉西坦组癫痫发作16%(3/19)vs 安慰剂组43%(10/23),比值比0.16(95%CI 0.03-0.94,p=0.043)。
- 所有72小时内发作均为脑电图发作,无临床发作。
- 左乙拉西坦组最常见治疗中出现的不良事件为头痛(39% vs 24%)、疼痛(13% vs 40%)和跌倒(30% vs 16%)。
核心结论
- 左乙拉西坦可能有效预防脑出血急性期癫痫发作。
- 需要更大规模的研究来确定预防性抗癫痫治疗是否能改善脑出血患者的功能预后。
研究设计与样本
- 双盲、随机、安慰剂对照的3期PEACH试验,在法国3个卒中单元进行。
- 纳入50例年龄≥18岁、发病24小时内的非创伤性脑出血患者,按1:1随机分配至左乙拉西坦(静脉500 mg每12小时)或匹配安慰剂,治疗持续6周。
- 随机化通过基于网络的系统完成,按中心和基线美国国立卫生研究院卒中量表(NIHSS)评分分层。
- 纳入后24小时内开始连续脑电图(EEG)监测并记录48小时。
- 主要终点为纳入后72小时内出现至少一次临床癫痫发作或连续EEG记录到至少一次脑电图发作,在改良意向治疗人群中分析(所有随机分配并完成连续EEG的患者)。
主要发现
- 2017年6月1日至2020年4月14日,共纳入50例轻至中度脑出血患者:24例分配至左乙拉西坦组,26例分配至安慰剂组。
- 72小时内,左乙拉西坦组19例中3例(16%)出现临床或脑电图癫痫发作,安慰剂组23例中10例(43%)出现(比值比0.16,95%CI 0.03-0.94,p=0.043)。
- 72小时内所有癫痫发作均为单纯脑电图发作。
- 1个月或3个月时,两组抑郁或焦虑报告无差异:抑郁在左乙拉西坦组3例(13%)vs 安慰剂组4例(15%),焦虑在左乙拉西坦组2例(8%)vs 安慰剂组1例(4%)。
- 左乙拉西坦组 vs 安慰剂组最常见的治疗中出现的不良事件:头痛(9例[39%] vs 6例[24%])、疼痛(3例[13%] vs 10例[40%])、跌倒(7例[30%] vs 4例[16%])。
关键数值与推荐
- 主要终点:72小时内临床或脑电图癫痫发作,左乙拉西坦组16%(3/19)vs 安慰剂组43%(10/23),比值比0.16(95%CI 0.03-0.94,p=0.043)。
- 抑郁:左乙拉西坦组13%(3/24)vs 安慰剂组15%(4/26);焦虑:左乙拉西坦组8%(2/24)vs 安慰剂组4%(1/26)。
- 头痛:左乙拉西坦组39%(9/24)vs 安慰剂组24%(6/26);疼痛:13%(3/24)vs 40%(10/26);跌倒:30%(7/24)vs 16%(4/26)。
- 神经功能恶化:左乙拉西坦组4%(1/24)vs 安慰剂组16%(4/26);重症肺炎:9%(2/24)vs 8%(2/26)。
临床怎么用
- 作者认为左乙拉西坦可能有效预防脑出血急性期癫痫发作。
- 作者指出需要更大规模的研究来确定预防性抗癫痫治疗是否能改善脑出血患者的功能预后。
局限性
- 招募在达到招募目标的48%时提前终止,原因是招募率低和资金停止。
- 作者指出需要更大规模的研究来确定预防性抗癫痫治疗是否能改善脑出血患者的功能预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence of early seizures (occurring within 7 days of stroke onset) after intracerebral haemorrhage reaches 30% when subclinical seizures are diagnosed by continuous EEG. Early seizures might be associated with haematoma expansion and worse neurological outcomes. Current guidelines do not recommend prophylactic antiseizure treatment in this setting. We aimed to assess whether prophylactic levetiracetam would reduce the risk of acute seizures in patients with intracerebral haemorrhage. METHODS: The double-blind, randomised, placebo-controlled, phase 3 PEACH trial was conducted at three stroke units in France. Patients (aged 18 years or older) who presented with a non-traumatic intracerebral haemorrhage within 24 h after onset were randomly assigned (1:1) to levetiracetam (intravenous 500 mg every 12 h) or matching placebo. Randomisation was done with a web-based system and stratified by centre and National Institutes of Health Stroke Scale (NIHSS) score at baseline. Treatment was continued for 6 weeks. Continuous EEG was started within 24 h after inclusion and recorded over 48 h. The primary endpoint was the occurrence of at least one clinical seizure within 72 h of inclusion or at least one electrographic seizure recorded on continuous EEG, analysed in the modified intention-to-treat population, which comprised all patients who were randomly assigned to treatment and who had a continuous EEG performed. This trial was registered at ClinicalTrials.gov, NCT02631759, and is now closed. Recruitment was prematurely stopped after 48% of the recruitment target was reached due to a low recruitment rate and cessation of funding. FINDINGS: Between June 1, 2017, and April 14, 2020, 50 patients with mild-to-moderate severity intracerebral haemorrhage were included: 24 were assigned to levetiracetam and 26 to placebo. During the first 72 h, a clinical or electrographic seizure was observed in three (16%) of 19 patients in the levetiracetam group versus ten (43%) of 23 patients in the placebo group (odds ratio 0·16, 95% CI 0·03-0·94, p=0·043). All seizures in the first 72 h were electrographic seizures only. No difference in depression or anxiety reporting was observed between the groups at 1 month or 3 months. Depression was recorded in three (13%) patients who received levetiracetam versus four (15%) patients who received placebo, and anxiety was reported for two (8%) patients versus one (4%) patient. The most common treatment-emergent adverse events in the levetiracetam group versus the placebo group were headache (nine [39%] vs six [24%]), pain (three [13%] vs ten [40%]), and falls (seven [30%] vs four [16%]). The most frequent serious adverse events were neurological deterioration due to the intracerebral haemorrhage (one [4%] vs four [16%]) and severe pneumonia (two [9%] vs two [8%]). No treatment-related death was reported in either group. INTERPRETATION: Levetiracetam might be effective in preventing acute seizures in intracerebral haemorrhage. Larger studies are needed to determine whether seizure prophylaxis improves functional outcome in patients with intracerebral haemorrhage. FUNDING: French Ministry of Health.
引用
- Peter-Derex L, Philippeau F, Garnier P, et al. Safety and efficacy of prophylactic levetiracetam for prevention of epileptic seizures in the acute phase of intracerebral haemorrhage (PEACH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2022. PMID: 35963261. doi:10.1016/S1474-4422(22)00235-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。